Publications by authors named "A Ibn Sellam"

A growing body of evidence highlights the importance of microglia, the resident immune cells of the CNS, and their pro-inflammatory activation in the onset of many neurological diseases. Microglial proliferation, differentiation, and survival are highly dependent on the CSF-1 signaling pathway, which can be pharmacologically modulated by inhibiting its receptor, CSF-1R. Pharmacological inhibition of CSF-1R leads to an almost complete microglial depletion whereas treatment arrest allows for subsequent repopulation.

View Article and Find Full Text PDF
Article Synopsis
  • Candida spp. are prevalent opportunistic fungal pathogens, with a study in Palestine revealing an 11.6% infection rate among patients diagnosed in 2022.
  • The most common species identified were C. albicans (46.54%), followed by C. glabrata and C. tropicalis, with variations in susceptibility to antifungal treatments noted.
  • The study highlighted the higher incidence of infections in intensive care units and surgery departments, emphasizing the significant role of non-albicans Candida species in invasive infections.
View Article and Find Full Text PDF

has emerged as a significant healthcare-associated pathogen due to its multidrug-resistant nature. Ongoing constraints in the discovery and provision of new antifungals create an urgent imperative to design effective remedies to this pressing global blight. Herein, we screened a chemical library and identified aryl-carbohydrazide analogs with potent activity against both and the most prevalent human fungal pathogen, .

View Article and Find Full Text PDF

Antibiotic resistance continues to pose significant health challenges. Considering severe limitations in the discovery and supply of new antibiotics, there is an unmet need to design alternative and more effective strategies for addressing this global issue. Use of polymeric nanoparticles with cationic shell surfaces offers a highly promising approach to coupling their inherent bactericidal action with sustained delivery of small lipophilic microbicides.

View Article and Find Full Text PDF
Article Synopsis
  • Respiratory syncytial virus (RSV) is a major cause of lower respiratory infections in children, and a new monoclonal antibody, nirsevimab, was introduced in September 2023 to combat RSV.
  • A study was conducted on infants under 12 months old to evaluate the effectiveness of nirsevimab against RSV-bronchiolitis in outpatient settings, involving a comparison between RSV-positive and RSV-negative bronchiolitis patients.
  • The findings showed that nirsevimab reduced the risk of RSV-bronchiolitis by 79.7%, indicating its effectiveness in preventing this infection in young children during outpatient care.
View Article and Find Full Text PDF